Show simple item record

dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorNapoletano, Flavia
dc.contributor.authorChiappini, Stephania
dc.contributor.authorOrsolini, Laura
dc.contributor.authorGuirguis, Amira
dc.contributor.authorCorkery, John Martin
dc.contributor.authorBonaccorso, Stefania
dc.contributor.authorRicciardi, Angelo
dc.contributor.authorScherbaum, Norbert
dc.contributor.authorvento, alessandro
dc.date.accessioned2019-07-17T00:08:06Z
dc.date.available2019-07-17T00:08:06Z
dc.date.issued2019-04-23
dc.identifier.citationSchifano , F , Napoletano , F , Chiappini , S , Orsolini , L , Guirguis , A , Corkery , J M , Bonaccorso , S , Ricciardi , A , Scherbaum , N & vento , A 2019 , ' New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues ' , Current Addiction Reports , vol. 6 , no. 2 , pp. 140-152 . https://doi.org/10.1007/s40429-019-00249-z
dc.identifier.issn2196-2952
dc.identifier.otherPURE: 16551040
dc.identifier.otherPURE UUID: 1cd30df8-fd55-404b-a4f8-aba1d76e8a31
dc.identifier.otherORCID: /0000-0001-8255-0660/work/62748680
dc.identifier.otherScopus: 85082118180
dc.identifier.urihttp://hdl.handle.net/2299/21437
dc.descriptionsubmitted 16 01 2019; revised version submitted 08 02 2019; accepted final 03 04 2019
dc.description.abstractPurpose of the review: A significant increase in the number, type, and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic substances have historically been used in order to achieve altered states of consciousness such as dissociative states. We aimed here at describing both the large number of novel ketamine-like dissociatives and tryptamine/lysergamide/phenethylamine psychedelics available, whilst describing the acute/long term clinical scenarios most commonly associated with their intake. Recent findings: An updated overview of the clinical and clinical pharmacological issues related to some of the most popular NPS categories has been provided, describing both psychosis and remaining psychopathological issues related to them. Conclusions: Although the complex link between NPS and psychiatric illnesses is yet to be fully understood, NPS misuse is now a significant clinical issue and an increasing challenge for clinicians working in both mental health and emergency departments.en
dc.language.isoeng
dc.relation.ispartofCurrent Addiction Reports
dc.subjectNew psychoactive substances
dc.subjectNPS
dc.subjectdissociation
dc.subjectPsychedelics
dc.subjectdrug-induced psychosis
dc.subjectdrug misuse
dc.titleNew psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issuesen
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.date.embargoedUntil2020-04-23
rioxxterms.versionAM
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1007/s40429-019-00249-z
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record